Dosing complete for 53 subjects in Sildenafil Oral Suspension Bioavailability StudyInitiated dosing in 38 subjects in Sildenafil Oral Suspension Food-Effect StudyTop-line data from both studies...
Study will compare bioavailability of Sildenafil Oral Suspension and Viagra® tablets under fasted conditionsCompanion study will evaluate the effects of food on the bioavailability of Sildenafil Oral...
Company plans to initiate clinical trials in September 2023 to compare Sildenafil Oral Spray to Viagra® tablets, and effect of dose administration under fasted versus fed conditionsRepresents...
Planned bioequivalence study in healthy adult male subjects will compare the rate and extent of absorption of ASP-001 (Sildenafil Oral Spray) versus Viagra® tabletsCompanion food-effect study will...
Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands
Aspargo Laboratories, Inc. to leverage Laboratorio SIDUS’ ED market position to launch Sildenafil Oral Spray in Argentina via exclusive License and Supply AgreementsAspargo’s Sildenafil Oral Spray...
ENGLEWOOD CLIFFS, N.J. and DUBAI, United Arab Emirates, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Aspargo Laboratories, Inc. (“Aspargo”), a private specialty pharmaceutical company focused on commercializing an innovative oral spray formulation of sildenafil, the active ingredient in Viagra®1 (“Sildenafil Spray”) announced today that it has entered into an Exclusive License Agreement (the “License”) with Taiba Healthcare Group (“Taiba”), a leading healthcare marketing, distribution and retail pharmacies group in the Sultanate of Oman, with regional operations and presence. The License grants Taiba the exclusive right and license to market, promote, and distribute Sildenafil Spray in the territory described in the License (the “Territory”), which covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Lebanon, Egypt, and Iraq. Taiba will assume responsibility for and bear the cost of obtaining regulatory approval to market Sildenafil Spray in each jurisdiction in the Territory.
Aspargo Laboratories, Inc. and Laboratorios Vanquish, S.A. to jointly launch Sildenafil Oral Spray in Mexico via exclusive License and Distribution AgreementsMexico, Brazil, Argentina, and Columbia...
Immediate revenue and expansion of global footprint Acquisition transforms Aspargo into a revenue producing company European market entry positions Aspargo for commercialization of Sildenafil Oral...
ENGLEWOOD CLIFFS, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Aspargo Laboratories, Inc. (Aspargo), a privately held, clinical stage, specialty pharmaceutical company, announced today that it has entered into a definitive agreement with Farmalider, S.A. of Madrid, Spain to acquire the exclusive international patent rights related to a proprietary oral spray suspension formulation of sildenafil citrate (Sildenafil Oral Spray) for five million common shares. Aspargo acquired the exclusive U.S. patent rights covering Sildenafil Oral Spray from Farmalider, S.A. in January 2020.